Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARV-102 food and esomeprazole pharmacokinetics pilot study in healthy participants
NL-OMON59352Phase 1Completed
- Sponsor
- Arvinas
- Start
- Nov 2025
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ARV-102 in parkinsonism (2 cohorts), sponsored by Arvinas. Started Nov 2025; status: completed.
02
Drugs
ARV-102
03
Conditions
parkinsonism
Beyond the preview
Go deeper on NL-OMON59352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59352.